MRNA vs TTD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 06, 2026

MRNA

48.8
AI Score
VS
MRNA Wins

TTD

48.4
AI Score

Investment Advisor Scores

MRNA

49score
Recommendation
HOLD

TTD

48score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA TTD Winner
Revenue 534.00M 688.86M TTD
Net Income -2.13B 40.00M TTD
Net Margin -397.9% 5.8% TTD
Operating Income -2.20B 66.65M TTD
ROE -31.4% 1.6% TTD
ROA -19.4% 0.7% TTD
Total Assets 10.96B 5.73B MRNA
Cash 1.72B 878.38M MRNA
Current Ratio 2.29 1.68 MRNA
Free Cash Flow -1.25B 279.06M TTD

Relative Price Performance (Last 90 Days)

MRNA 1M: -23.7% · 3M: +20.3% TTD 1M: -30.1% · 3M: -41.2%

Current Technical Phase

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 49

RSI (14): 49.0 · Price: $58.39

TTD

Markdown
Sell / avoid

Price below a falling SMA50 (slope -8.2%), weak momentum, RSI 28

RSI (14): 28.3 · Price: $13.82

Fundamentals Snapshot

Metric MRNA TTD
Market Cap
Forward P/E -11.0 6.4
Trailing P/E 21.0
Revenue (TTM)
Revenue Growth 0.0% 0.1%
Gross Margin -0.7% 0.8%
Operating Margin -5.6% 0.1%
EPS -7.88 0.84
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.